French President Francois Hollande Invites Stanford University Hall of Fame Inventor Dr Philippe Pouletty, Chairman of ABIVAX Biotech Company on His Visit to Cuba May 11

Share Article

Pouletty holds 29 US patents; has met with multiple Cuban officials, and has been developing innovative drugs with the Cubans for several years. Historic visit underlines the strong and pioneering position of ABIVAX with Biotechnology centers in Havana.

[May 11th, New York, NY] ABIVAX, a biotech company focused on the discovery, development and commercialization of anti-viral therapies, founded by Stanford University Hall of Fame Inventor Philippe Pouletty, MD, announced today he is accompanying French President Francois Hollande on his first visit to Cuba on May 11, 2015 and will attend the dinner hosted by President Raul Castro and President François Hollande the evening of May 11th. This historic visit is the first time a French President has set foot on Cuban soil. The visit of prominent European Head of State comes just weeks after the historic move of Mr. Obama and Mr. Castro to reestablish diplomatic relations between Cuba and the United States.

In making the announcement Dr Pouletty – who is on his second visit to Cuba this year - said, "ABIVAX has long recognized the excellence of research and industrial production of vaccines and biological products from Cuba and was able to build relationships with the Center for Genetic Engineering and Biotechnology (CIGB) for nearly 5 years, and more recently, with the Finlay Institute. Abivax is honored that President Hollande will see the great work Cuban and French scientists are doing together to fight severe viral diseases.” Dr Pouletty recently attended the first NASDAQ summit held on Cuba business opportunities and economic investment, which took place in New York in April. He also appeared on CNBC and contributed to the Huffington Post.

ABIVAX is a pioneering player in the western Pharma and Biotech industry that has positioned itself to partner with Cuba for multiple projects. These relationships have already resulted in a number of important agreements for ABIVAX including the in-licensing of first-in class ABX203 (a novel therapeutic vaccine to treat chronic hepatitis B), as well as a first-in-class anti-viral compound against Dengue, and the acquisition of some distribution rights of 3 commercial vaccines against Typhoid, Meningococcus B&C, and Leptospirosis.

ABIVAX has set its goal to become a global leader in anti-viral treatments with a long-lasting therapeutic effect to treat some of the world’s most threatening viral diseases: HIV, Chronic Hepatitis B, Dengue, Ebola, and Chikungunya. Although ABIVAX has other major projects aside its Cuban partnerships, ABIVAX see its partnership with CIGB a priority, with Pouletty adding, “ABIVAX is co-developing, licensing and commercializing several products from Cuba, which is a country of international standing in the field of healthcare, and was able to establish balanced relations between complementary partners."

President Hollande will meet with several CIGB and BioCubaFarma executives. Today, the Cuban life science industry is based on cutting edge science and technology research, with more than 500 vaccines, biologics and commercialized drugs. They have also developed high quality manufacturing capabilities recognised by WHO, with competitive costs of goods.

Speaking about the important partnership in Cuba, Prof. Hartmut Ehrlich, MD, CEO of ABIVAX said, "We are proud of our collaborations with these excellent institutions from Cuba, which are developing and manufacturing high quality biologics. Additional agreements are under discussion."

Further information can be found at http://www.abivax.com

US press should contact:

Ian Bailey
IBailey(at)CaptialCPartners(dot)com

Nicolla Hewitt
NHewitt(at)CaptialCPartners(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicolla Hewitt
Visit website